Bibliography
- Stead AH , HookW, MoffatAC, BerryD: Therapeutic, toxic and fatal blood data.Hum. Toxicol.2, 135–147 (1983).
- Eadie MJ : Plasma antiepileptic drug monitoring in a neurological practice: 25 years experience.Therap. Drug Monitoring16, 458–468 (1994).
- Schmidt D , EinickeI, HaenelF: The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine.Arch. Neurol.43, 263–265 (1986).
- Norell E , LilienbergG, GamstorpI: Systematic determination of the serum phenytoin level as an aid in the management of children with epilepsy.Eur. Neurol.13, 232–244 (1975).
- Wolf P , PastuchovaT, MaataringaM. Decline in seizure propensity in seizure-free patients as reflected in the evolution of the therapeutic antiepileptic drug threshold. Epilepsy and Behavior8, 384–390 (2006).
- Murdoch D , Lyseng-WilliamsonKA: Subcutaneous recombinant interferon-1α (Rebif).Drugs65, 1295–1312 (2005).
- Sternieri E , PinettiD, CocciaCPR, Leone S, Betrolini A, Ferrari A: Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J. Headache Pain6, 319–321 (2005).
- Schwid SR , ThorpeJ, ShariefMet al.: Enhanced benefit of increasing interferon β-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study.Arch. Neurol.61, 785–792 (2005).
- Jhee SS , ShiovitzT, CrawfordAW, Cutler NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin. Pharmacokinetics40, 189–205 (2001).
- Volans GN : The effect of metoclopramide on the absorption of effervescent aspirin in migraine.Br. J. Clin. Pharmacol.2, 57–63 (1975).
- Ross-Lee LM , EadieMJ, HeazlewoodV, BochnerF, TyrerJH: Aspirin pharmacokinetics in migraine. The effect of metoclopramide.Eur. J. Clin. Pharmacol.24, 777–785 (1983).
- Chan LS , NuttJG, HolfordNHG: Modelling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson‘s disease.J. Pharmacokinetics Biopharmaceutics31, 243–268 (2004).
- Deleu D , NorthwayMG, HanssensY: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson‘s disease.Clin. Pharmacokinetics41, 261–309 (2002).
- Black KJ , CarlJL, HartleinJM, WarrenSL, HersheyT, PerlmutterJS: Rapid intravenous loading of levodopa for human research: clinical results.J. Neurosci. Methods127, 19–29 (2003).
- Stocchi F , VaccaL, RuggieriS, OlanowCW: Intermittent vs continuous levodopa administration in patients with advanced Parkinson‘s disease.Arch. Neurol.62, 905–910 (2005).